{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:00:28Z","timestamp":1784923228390,"version":"3.55.0"},"reference-count":108,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Anti-M\u00fcllerian hormone (AMH) is widely used to assess gonadotoxicity related to anti-cancer treatments and to measure ovarian function in cancer survivors. The extent of AMH decline across malignancies and treatment regimens and the degree of subsequent recovery have not been systematically quantified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE AND RATIONALE<\/jats:title>\n                    <jats:p>The primary objective of this review was to quantify the change in AMH following cancer treatment and to model longitudinal AMH trajectories in survivors. The secondary objective was to compare AMH trajectories in cancer survivors with those of age-matched non-cancer controls. Data on long-term ovarian reserve after cancer treatment remain limited. This study integrates recent evidence and age-matched control data to better distinguish treatment-related AMH decline from normal reproductive ageing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SEARCH METHODS<\/jats:title>\n                    <jats:p>A systematic search was performed across CENTRAL, MEDLINE, Google Scholar, Embase, and MedRxiv from inception until 24 January 2024, with an updated search on 19 March 2026. Both MEDLINE and Embase were searched via the Ovid platform, whilst Emtree index terms were used for EMBASE. The search strategy combined both index terms and free-text terms: (gonadotoxicity OR premature menopause OR premature ovarian insufficiency (POI) OR premature ovarian failure (POF)) AND (AMH OR Antimullerian* OR Anti-Mullerian) AND cancer. Studies were included if they involved female cancer patients of any age, including paediatric, adolescent and young adult (AYA), and adult populations, who received chemotherapy and who reported either pre- and post-treatment AMH levels or AMH measurements at defined time points after treatment. Studies were excluded if they did not report quantitative AMH data, involved male patients or non-human subjects, or included studies unrelated to cancer treatment-induced gonadotoxicity. The primary outcome was percentage change in AMH from baseline to 12 and 24\u2009months from the end of treatment. Secondary outcomes included long-term AMH trajectories in adult and paediatric cancer survivors compared to the age-related decline in healthy controls. Risk of bias was assessed using the Joanna Briggs Institute (JBI) study-design-specific critical appraisal tools, and certainty of evidence was evaluated using GRADE. Analyses were performed in GraphPad Prism v10.6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OUTCOMES<\/jats:title>\n                    <jats:p>Across all four cohorts (breast, lymphoma, thyroid, and paediatric\/AYA mixed cancers), AMH levels were higher at 12 and 24\u2009months compared with 6\u2009months from the end of treatment. With breast cancer (median age 37.8\u2009years, n\u2009=\u20092259), AMH was reduced by 76.4% at 12\u2009months (95% CI: \u221293.5 to \u221255.7; 24 studies; GRADE: moderate-certainty evidence). With lymphoma, ABVD treatment regimens (median age 24\u2009years, n\u2009=\u2009146) were associated with a smaller reduction in AMH at 12\u2009months (\u221221.1%; 95% CI: \u221281.6 to +14.8; four studies; GRADE: low-certainty evidence), whereas non-ABVD regimens (median age 26.3\u2009years, n\u2009=\u2009188) were associated with a larger reduction (\u221290.1%; 95% CI: \u221296.1 to \u221268.3; six studies; GRADE: moderate-certainty evidence). With thyroid cancer (median age 32.5\u2009years, n\u2009=\u2009181), radioactive iodine treatment was associated with a 57.9% reduction in AMH at 12\u2009months (95% CI: \u221265.2 to \u221236.4; 4 studies; GRADE: high-certainty evidence). In the paediatric and AYA mixed cancers cohort (median age 9, n\u2009=\u2009176), AMH was reduced by 63.1% at 12\u2009months (95% CI: 64.3\u201361.9; four studies; GRADE: very low-certainty evidence). Among the adult and paediatric survivors who retained ovarian function, AMH trajectories remained relatively stable and closely aligned with age-matched healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS<\/jats:title>\n                    <jats:p>AMH levels consistently improved between 6 and 12\u201324\u2009months from the end of cancer treatment. We provide generalizable estimates of AMH trajectories in female survivors of both childhood and young adult cancer, indicating that their long-term AMH declines are similar to those of age-matched controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>PROSPERO registration number: CRD420251000939.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humupd\/dmag019","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:00:14Z","timestamp":1784919614000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing the reproductive lifespan of female cancer survivors using AMH: a meta-synthesis of longitudinal studies"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3086-5235","authenticated-orcid":false,"given":"Neerujah","family":"Balachandren","sequence":"first","affiliation":[{"name":"Reproductive Medicine Unit, University College London Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula L","family":"Kastora","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Unit, University College London Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-518X","authenticated-orcid":false,"given":"Richard A","family":"Anderson","sequence":"additional","affiliation":[{"name":"Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh , Edinburgh,","place":["UK"]},{"name":"Elizabeth Garrett Anderson Institute for Women\u2019s Health, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Luehwink","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Unit, University College London Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie C","family":"Davies","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Unit, University College London Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A","family":"Lavery","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Unit, University College London Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mavrelos","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Unit, University College London Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephia","family":"Yasmin","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Unit, University College London Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072415000797000_dmag019-B1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2010-2582","article-title":"Pretreatment serum anti-M\u00fcllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer","volume":"96","author":"Anderson","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072415000797000_dmag019-B2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2265.2011.04100.x","article-title":"Fertility preservation in girls and young women","volume":"75","author":"Anderson","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026072415000797000_dmag019-B3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.maturitas.2011.11.008","article-title":"Measuring anti-M\u00fcllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated?","volume":"71","author":"Anderson","year":"2012","journal-title":"Maturitas"},{"key":"2026072415000797000_dmag019-B4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2017.10.001","article-title":"The utility of anti-M\u00fcllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer","volume":"87","author":"Anderson","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026072415000797000_dmag019-B5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin\u2019s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026072415000797000_dmag019-B6","doi-asserted-by":"crossref","first-page":"574263","DOI":"10.3389\/fendo.2020.574263","article-title":"The clinical value and interpretation of anti-M\u00fcllerian hormone in women with cancer","volume":"11","author":"Anderson","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026072415000797000_dmag019-B7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-021-06508-w","article-title":"Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer","volume":"192","author":"Anderson","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2026072415000797000_dmag019-B9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026072415000797000_dmag019-B10","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1634\/theoncologist.2015-0044","article-title":"Long-term follow-up of chemotherapy-induced ovarian failure in young breast cancer patients: the role of vascular toxicity","volume":"20","author":"Ben-Aharon","year":"2015","journal-title":"Oncologist"},{"key":"2026072415000797000_dmag019-B11","doi-asserted-by":"crossref","first-page":"102035","DOI":"10.1016\/j.jogoh.2020.102035","article-title":"Evaluation of ovarian reserve before and after chemotherapy","volume":"50","author":"Berjeb","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2026072415000797000_dmag019-B12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1210\/jc.2011-3180","article-title":"Anti-M\u00fcllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study","volume":"97","author":"Brougham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072415000797000_dmag019-B13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1210\/jc.2018-02257","article-title":"Differential rates of change in measures of ovarian reserve in young cancer survivors across the reproductive lifespan","volume":"104","author":"Cameron","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072415000797000_dmag019-B14","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/humrep\/del165","article-title":"Anti-M\u00fcllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro","volume":"21","author":"Carlsson","year":"2006","journal-title":"Hum Reprod"},{"key":"2026072415000797000_dmag019-B16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s11764-014-0364-4","article-title":"Anti-M\u00fcllerian hormone screening to assess ovarian reserve among female survivors of childhood cancer","volume":"8","author":"Charpentier","year":"2014","journal-title":"J Cancer Surviv"},{"key":"2026072415000797000_dmag019-B17","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S1470-2045(23)00390-X","article-title":"Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement","volume":"24","author":"Cui","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026072415000797000_dmag019-B18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.rbmo.2018.02.004","article-title":"Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy","volume":"36","author":"Decanter","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2026072415000797000_dmag019-B19","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/humrep\/deab189","article-title":"Longitudinal study of AMH variations in 122 adolescents and young adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling","volume":"36","author":"Decanter","year":"2021","journal-title":"Hum Reprod"},{"key":"2026072415000797000_dmag019-B20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.rbmo.2009.11.010","article-title":"Anti-M\u00fcllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results","volume":"20","author":"Decanter","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"2026072415000797000_dmag019-B21","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2015.65.8864","article-title":"No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial","volume":"34","author":"Demeestere","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026072415000797000_dmag019-B22","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.21.00068","article-title":"Gonadal function recovery in patients with advanced Hodgkin lymphoma treated with a PET-adapted regimen: prospective analysis of a randomized phase III trial (AHL2011)","volume":"39","author":"Demeestere","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026072415000797000_dmag019-B23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2017.03.035","article-title":"Prospective evaluation of serum anti-M\u00fcllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer","volume":"79","author":"Dezellus","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026072415000797000_dmag019-B24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1634\/theoncologist.2013-0138","article-title":"Anti-M\u00fcllerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies","volume":"18","author":"Di Paola","year":"2013","journal-title":"Oncologist"},{"key":"2026072415000797000_dmag019-B25","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/pbc.24701","article-title":"Pregnancy after cancer: results from a prospective cohort study of cancer survivors","volume":"60","author":"Dillon","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2026072415000797000_dmag019-B26","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/humrep\/deae112","article-title":"The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-M\u00fcllerian hormone","volume":"39","author":"Drechsel","year":"2024","journal-title":"Hum Reprod"},{"key":"2026072415000797000_dmag019-B27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1634\/theoncologist.2019-0837","article-title":"It is time to talk about fertility and immunotherapy","volume":"25","author":"Duma","year":"2020","journal-title":"Oncologist"},{"key":"2026072415000797000_dmag019-B28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpag.2016.02.009","article-title":"Low anti-M\u00fcllerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy","volume":"29","author":"Elchuri","year":"2016","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"2026072415000797000_dmag019-B29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/AOG.0b013e31827374e2","article-title":"Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial","volume":"121","author":"Elgindy","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2026072415000797000_dmag019-B30","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1080\/10428194.2021.1901093","article-title":"Long-term ovarian reserve and fertility outcomes in female survivors of childhood acute lymphoblastic leukemia","volume":"62","author":"Elitzur","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2026072415000797000_dmag019-B31","doi-asserted-by":"crossref","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","article-title":"ESHRE guideline: female fertility preservation","volume":"2020","author":"ESHRE Guideline Group on Female Fertility Preservation;","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2026072415000797000_dmag019-B32","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1089\/thy.2018.0129","article-title":"Effects of radioactive iodine therapy on ovarian reserve: a prospective pilot study","volume":"28","author":"Evranos","year":"2018","journal-title":"Thyroid"},{"key":"2026072415000797000_dmag019-B33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(25)00262-1","article-title":"Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial","volume":"26","author":"Ferdinandus","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026072415000797000_dmag019-B34","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3109\/10428194.2015.1118476","article-title":"Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas","volume":"57","author":"Gharwan","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2026072415000797000_dmag019-B35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10549-020-05933-7","article-title":"Impact of adjuvant chemotherapy or tamoxifen alone on the ovarian reserve of young women with breast cancer","volume":"185","author":"Goldfarb","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2026072415000797000_dmag019-B36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jpag.2016.04.009","article-title":"Anti-M\u00fcllerian hormone in female adolescent cancer patients before, during, and after completion of therapy: a pilot feasibility study","volume":"29","author":"Gupta","year":"2016","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"2026072415000797000_dmag019-B37","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026072415000797000_dmag019-B38","doi-asserted-by":"crossref","first-page":"101742","DOI":"10.1016\/j.eclinm.2022.101742","article-title":"AMH concentrations in infancy and mid-childhood predict ovarian activity in adolescence: a long-term longitudinal study of healthy girls","volume":"55","author":"Hagen","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026072415000797000_dmag019-B39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pbc.23363","article-title":"Gonadal function and parenthood 20 years after treatment for childhood lymphoma: a cross-sectional study","volume":"59","author":"Hamre","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"2026072415000797000_dmag019-B40","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.rbmo.2015.12.008","article-title":"Anti-M\u00fcllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies","volume":"32","author":"Hamy","year":"2016","journal-title":"Reprod Biomed Online"},{"key":"2026072415000797000_dmag019-B41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1634\/theoncologist.2013-0145","article-title":"Prediction of postchemotherapy ovarian function using markers of ovarian reserve","volume":"19","author":"Henry","year":"2014","journal-title":"Oncologist"},{"key":"2026072415000797000_dmag019-B42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.fertnstert.2015.11.020","article-title":"Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all","volume":"105","author":"Jacobson","year":"2016","journal-title":"Fertil Steril"},{"key":"2026072415000797000_dmag019-B43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/molehr\/gat024","article-title":"Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection","volume":"19","author":"Jeppesen","year":"2013","journal-title":"Mol Hum Reprod"},{"key":"2026072415000797000_dmag019-B44","doi-asserted-by":"crossref","first-page":"992","DOI":"10.4143\/crt.2022.1518","article-title":"Gonadal function in female adolescent and young adult survivors of childhood cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Cancer Res Treat"},{"key":"2026072415000797000_dmag019-B45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.6065\/apem.2448146.073","article-title":"Assessing the ovarian reserve in girls who survived childhood leukemia using anti-M\u00fcllerian hormone","volume":"30","author":"Jingrukwong","year":"2025","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"2026072415000797000_dmag019-B46","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1530\/EC-18-0180","article-title":"Post-chemotherapy serum anti-M\u00fcllerian hormone level predicts ovarian function recovery","volume":"7","author":"Kim","year":"2018","journal-title":"Endocr Connect"},{"key":"2026072415000797000_dmag019-B47","doi-asserted-by":"crossref","first-page":"125080","DOI":"10.1155\/2013\/125080","article-title":"Anti-M\u00fcllerian hormone as a sensitive marker of ovarian function in young cancer survivors","volume":"2013","author":"Krawczuk-Rybak","year":"2013","journal-title":"Int J Endocrinol"},{"key":"2026072415000797000_dmag019-B48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1055\/s-0033-1349854","article-title":"The progressive reduction in the ovarian reserve in young women after anticancer treatment","volume":"45","author":"Krawczuk-Rybak","year":"2013","journal-title":"Horm Metab Res"},{"key":"2026072415000797000_dmag019-B49","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/hon.2681","article-title":"The influence of different intensity of treatment on hormonal markers of gonadal function in acute lymphoblastic leukemia survivors","volume":"37","author":"Krawczuk-Rybak","year":"2019","journal-title":"Hematol Oncol"},{"key":"2026072415000797000_dmag019-B50","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/jnci\/djaf198","article-title":"Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients","volume":"117","author":"Lambertini","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026072415000797000_dmag019-B51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/annonc\/mdx639","article-title":"Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients","volume":"29","author":"Lambertini","year":"2018","journal-title":"Ann Oncol"},{"key":"2026072415000797000_dmag019-B52","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data","volume":"36","author":"Lambertini","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026072415000797000_dmag019-B53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fonc.2019.00575","article-title":"Impact of taxanes, endocrine therapy, and deleterious germline BRCA mutations on anti-M\u00fcllerian hormone levels in early breast cancer patients treated with anthracycline- and cyclophosphamide-based chemotherapy","volume":"9","author":"Lambertini","year":"2019","journal-title":"Front Oncol"},{"key":"2026072415000797000_dmag019-B54","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"key":"2026072415000797000_dmag019-B55","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10549-018-4863-2","article-title":"Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy","volume":"171","author":"Lee","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2026072415000797000_dmag019-B56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fonc.2020.00863","article-title":"Prediction of successful ovarian protection using gonadotropin-releasing hormone agonists during chemotherapy in young estrogen receptor-negative breast cancer patients","volume":"10","author":"Lee","year":"2020","journal-title":"Front Oncol"},{"key":"2026072415000797000_dmag019-B57","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/annonc\/mdx184","article-title":"GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial","volume":"28","author":"Leonard","year":"2017","journal-title":"Ann Oncol"},{"key":"2026072415000797000_dmag019-B58","first-page":"8171","year":"2020"},{"key":"2026072415000797000_dmag019-B59","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/humrep\/den487","article-title":"Assessment of ovarian reserve in adult childhood cancer survivors using anti-M\u00fcllerian hormone","volume":"24","author":"Lie Fong","year":"2009","journal-title":"Hum Reprod"},{"key":"2026072415000797000_dmag019-B60","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2013.49.2678","article-title":"Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Loren","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026072415000797000_dmag019-B61","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejogrb.2020.09.016","article-title":"Evolution of serum anti-M\u00fcllerian hormone level in young women treated with chemotherapy for breast cancer according to basal AMH level","volume":"254","author":"Loubersac","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026072415000797000_dmag019-B62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.fertnstert.2013.08.052","article-title":"Anti-M\u00fcllerian hormone as a measure of reproductive function in female childhood cancer survivors","volume":"101","author":"Lunsford","year":"2014","journal-title":"Fertil Steril"},{"key":"2026072415000797000_dmag019-B63","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/sj.bjc.6603814","article-title":"Predictors of ovarian reserve in young women with breast cancer","volume":"96","author":"Lutchman Singh","year":"2007","journal-title":"Br J Cancer"},{"key":"2026072415000797000_dmag019-B64","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00404-017-4581-8","article-title":"Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia","volume":"297","author":"Malisic","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"2026072415000797000_dmag019-B65","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/GRF.0b013e3181f96b54","article-title":"Toxicity of chemotherapy and radiation on female reproduction","volume":"53","author":"Meirow","year":"2010","journal-title":"Clin Obstet Gynecol"},{"key":"2026072415000797000_dmag019-B66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13044-020-0075-z","article-title":"Cross-sectional and prospective study on anti-M\u00fcllerian hormone changes in a cohort of pre-menopausal women with a history of differentiated thyroid cancer","volume":"13","author":"Mittica","year":"2020","journal-title":"Thyroid Res"},{"key":"2026072415000797000_dmag019-B67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000346139","article-title":"Low serum concentrations of anti-M\u00fcllerian hormone are common in 53 female childhood cancer survivors","volume":"79","author":"Miyoshi","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"2026072415000797000_dmag019-B68","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.3747\/co.24.3335","article-title":"Ovarian function after chemotherapy in young breast cancer survivors","volume":"24","author":"Morarji","year":"2017","journal-title":"Curr Oncol"},{"key":"2026072415000797000_dmag019-B69","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/humupd\/dms022","article-title":"How do chemotherapeutic agents damage the ovary?","volume":"18","author":"Morgan","year":"2012","journal-title":"Hum Reprod Update"},{"key":"2026072415000797000_dmag019-B70","doi-asserted-by":"crossref","first-page":"e4512","DOI":"10.1097\/MD.0000000000004512","article-title":"Severe gonadotoxic insult manifests early in young girls treated for Ewing sarcoma","volume":"95","author":"M\u00f6rse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026072415000797000_dmag019-B71","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S1470-2045(20)30594-5","article-title":"Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026072415000797000_dmag019-B72","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.fertnstert.2013.10.021","article-title":"Reference range for the anti-m\u00fcllerian hormone Generation II assay: a population study of 10,984 women, with comparison to the established Diagnostics Systems Laboratory nomogram","volume":"101","author":"Nelson","year":"2014","journal-title":"Fertil Steril"},{"key":"2026072415000797000_dmag019-B73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.rbmo.2013.04.003","article-title":"A 10-year follow up of reproductive function in women treated for childhood cancer","volume":"27","author":"Nielsen","year":"2013","journal-title":"Reprod Biomed Online"},{"key":"2026072415000797000_dmag019-B74","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1089\/thy.2019.0560","article-title":"Long-term effects of radioiodine treatment on female fertility in survivors of childhood differentiated thyroid carcinoma","volume":"30","author":"Nies","year":"2020","journal-title":"Thyroid"},{"key":"2026072415000797000_dmag019-B75","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/aogs.14290","article-title":"A survey of ovarian reserve and quality of life in female survivors of pediatric cancer","volume":"101","author":"Nilsson","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2026072415000797000_dmag019-B76","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00404-009-1308-5","article-title":"GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin\u2019s lymphoma patients","volume":"282","author":"Nitzschke","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"2026072415000797000_dmag019-B77","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/0284186X.2018.1529423","article-title":"Anti-m\u00fcllerian hormone compared with other ovarian markers after childhood cancer treatment","volume":"58","author":"Nystr\u00f6m","year":"2019","journal-title":"Acta Oncol"},{"key":"2026072415000797000_dmag019-B78","doi-asserted-by":"crossref","first-page":"e210046","DOI":"10.1530\/ETJ-21-0046","article-title":"2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?","volume":"11","author":"Pacini","year":"2022","journal-title":"Eur Thyroid J"},{"key":"2026072415000797000_dmag019-B79","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026072415000797000_dmag019-B80","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.rbmo.2019.06.001","article-title":"Five-year study assessing the clinical utility of anti-M\u00fcllerian hormone measurements in reproductive-age women with cancer","volume":"39","author":"Palinska-Rudzka","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2026072415000797000_dmag019-B81","doi-asserted-by":"crossref","first-page":"hoae065","DOI":"10.1093\/hropen\/hoae065","article-title":"Evidence-based guideline: premature ovarian insufficiency","volume":"2024","author":"Panay","year":"2024","journal-title":"Hum Reprod Open"},{"key":"2026072415000797000_dmag019-B82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/jpem-2020-0272","article-title":"Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk","volume":"34","author":"Parissone","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2026072415000797000_dmag019-B83","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.22.01885","article-title":"Cancer treatment-related ovarian dysfunction in women of childbearing potential: management and fertility preservation options","volume":"41","author":"Reynolds","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026072415000797000_dmag019-B84","doi-asserted-by":"crossref","first-page":"e28894","DOI":"10.1002\/pbc.28894","article-title":"Female reproductive function after treatment of childhood acute lymphoblastic leukemia","volume":"68","author":"Roshandel","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2026072415000797000_dmag019-B85","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1089\/jayao.2024.0111","article-title":"Limited recommendations and evidence for timing and frequency of Anti-Mullerian Hormone screening in female pediatric cancer survivors: a systematic review from the Pediatric and Adolescent Committee of the Oncofertility Consortium","volume":"14","author":"Rotz","year":"2025","journal-title":"J Adolesc Young Adult Oncol"},{"key":"2026072415000797000_dmag019-B86","doi-asserted-by":"crossref","first-page":"hoaa045","DOI":"10.1093\/hropen\/hoaa045","article-title":"Clinical summary guide: reproduction in women with previous abdominopelvic radiotherapy or total body irradiation","volume":"2020","author":"Rozen","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2026072415000797000_dmag019-B87","volume-title":"GRADE Working Group","author":"Sch\u00fcnemann","year":"2013"},{"key":"2026072415000797000_dmag019-B88","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.fertnstert.2016.10.020","article-title":"Impact of tamoxifen therapy on fertility in breast cancer survivors","volume":"107","author":"Shandley","year":"2017","journal-title":"Fertil Steril"},{"key":"2026072415000797000_dmag019-B89","doi-asserted-by":"crossref","first-page":"e240511","DOI":"10.1530\/EC-24-0511","article-title":"Ovarian function in adolescents and young adults undergoing cancer treatment: biochemical and ultrasound marker analysis","volume":"14","author":"Signorino","year":"2025","journal-title":"Endocr Connect"},{"key":"2026072415000797000_dmag019-B90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13048-019-0581-6","article-title":"Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments","volume":"12","author":"Silva","year":"2019","journal-title":"J Ovarian Res"},{"key":"2026072415000797000_dmag019-B91","doi-asserted-by":"crossref","first-page":"e240046","DOI":"10.1530\/RAF-24-0046","article-title":"Age and serum anti-M\u00fcllerian hormone levels as predictors of time to return of menses after chemotherapy","volume":"6","author":"Singh","year":"2025","journal-title":"Reprod Fertil"},{"key":"2026072415000797000_dmag019-B92","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026072415000797000_dmag019-B93","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1210\/clinem\/dgaa172","article-title":"Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH","volume":"105","author":"Su","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072415000797000_dmag019-B94","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.24746","article-title":"Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors","volume":"116","author":"Su","year":"2010","journal-title":"Cancer"},{"key":"2026072415000797000_dmag019-B95","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/humrep\/dev060","article-title":"Ovarian reserve after treatment with alkylating agents during childhood","volume":"30","author":"Thomas-Teinturier","year":"2015","journal-title":"Hum Reprod"},{"key":"2026072415000797000_dmag019-B96","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/humrep\/des391","article-title":"Age at menopause and its influencing factors in a cohort of survivors of childhood cancer: earlier but rarely premature","volume":"28","author":"Thomas-Teinturier","year":"2013","journal-title":"Hum Reprod"},{"key":"2026072415000797000_dmag019-B97","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.breast.2017.07.007","article-title":"Anti-M\u00fcllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy: a translational research project of the SUCCESS A study","volume":"35","author":"Trapp","year":"2017","journal-title":"Breast"},{"key":"2026072415000797000_dmag019-B98","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2006-2374","article-title":"Anti-M\u00fcllerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin\u2019s lymphoma during childhood","volume":"92","author":"van Beek","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072415000797000_dmag019-B99","first-page":"193","article-title":"Longitudinal follow-up in female childhood cancer survivors: no signs of accelerated ovarian function loss","volume":"32","author":"van der Kooi","year":"2017","journal-title":"Hum Reprod"},{"key":"2026072415000797000_dmag019-B100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2019.01.104","article-title":"Perinatal complications in female survivors of cancer: a systematic review and meta-analysis","volume":"111","author":"van der Kooi","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026072415000797000_dmag019-B101","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1089\/thy.2019.0504","article-title":"Longitudinal analysis of the effect of radioiodine therapy on ovarian reserve in females with differentiated thyroid cancer","volume":"30","author":"van Velsen","year":"2020","journal-title":"Thyroid"},{"key":"2026072415000797000_dmag019-B102","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/humrep\/deg016","article-title":"The radiosensitivity of the human oocyte","volume":"18","author":"Wallace","year":"2003","journal-title":"Hum Reprod"},{"key":"2026072415000797000_dmag019-B103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/molehr\/gah015","article-title":"Anti-M\u00fcllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment","volume":"10","author":"Weenen","year":"2004","journal-title":"Mol Hum Reprod"},{"key":"2026072415000797000_dmag019-B104","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s12885-017-3593-x","article-title":"Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial","volume":"17","author":"Wenners","year":"2017","journal-title":"BMC Cancer"},{"key":"2026072415000797000_dmag019-B105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"key":"2026072415000797000_dmag019-B106","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/thy.2017.0442","article-title":"A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: results of a prospective pilot study","volume":"28","author":"Yaish","year":"2018","journal-title":"Thyroid"},{"key":"2026072415000797000_dmag019-B107","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/jayao.2024.0093","article-title":"A mega-analysis of Anti-M\u00fcllerian hormone levels in female childhood cancer survivors based on treatment risk, time since treatment, and pubertal status","volume":"14","author":"Yano Maher","year":"2025","journal-title":"J Adolesc Young Adult Oncol"},{"key":"2026072415000797000_dmag019-B108","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.25037","article-title":"Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy","volume":"116","author":"Yu","year":"2010","journal-title":"Cancer"},{"key":"2026072415000797000_dmag019-B109","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3109\/0284186X.2016.1155738","article-title":"Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis","volume":"55","author":"Zavos","year":"2016","journal-title":"Acta Oncol"},{"key":"2026072415000797000_dmag019-B110","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.7150\/jca.31859","article-title":"GnRHa for ovarian protection and the association between AMH and ovarian function during adjuvant chemotherapy for breast cancer","volume":"10","author":"Zhong","year":"2019","journal-title":"J Cancer"}],"container-title":["Human Reproduction Update"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humupd\/advance-article-pdf\/doi\/10.1093\/humupd\/dmag019\/69968604\/dmag019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humupd\/advance-article-pdf\/doi\/10.1093\/humupd\/dmag019\/69968604\/dmag019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:00:25Z","timestamp":1784919625000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humupd\/advance-article\/doi\/10.1093\/humupd\/dmag019\/8741618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":108,"URL":"https:\/\/doi.org\/10.1093\/humupd\/dmag019","relation":{},"ISSN":["1355-4786","1460-2369"],"issn-type":[{"value":"1355-4786","type":"print"},{"value":"1460-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"dmag019"}}